These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 33196710)

  • 1. [Therapeutic possibilities in KRAS-mutant lung adenocarcinoma].
    Radeczky P; Ghimessy Á; Berta J; László V; Hegedűs B; Rényi-Vámos F; Fillinger J; Megyesfalvi Z; Döme B
    Magy Onkol; 2020 Sep; 64(3):231-244. PubMed ID: 33196710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current therapy of KRAS-mutant lung cancer.
    Ghimessy A; Radeczky P; Laszlo V; Hegedus B; Renyi-Vamos F; Fillinger J; Klepetko W; Lang C; Dome B; Megyesfalvi Z
    Cancer Metastasis Rev; 2020 Dec; 39(4):1159-1177. PubMed ID: 32548736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Predictive relevance of KRAS mutational status in bone metastatic lung adenocarcinoma treated with bisphosphonate therapy].
    Radeczky P; Megyesfalvi Z; Fillinger J; László V; Rásó E; Moldvay J; Schlegl E; Barbai T; Bogos K; Tímár J; Rényi-Vámos F; Hegedűs B; Döme B
    Magy Onkol; 2021 Jun; 65(2):103-111. PubMed ID: 34081758
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Skoulidis F; Goldberg ME; Greenawalt DM; Hellmann MD; Awad MM; Gainor JF; Schrock AB; Hartmaier RJ; Trabucco SE; Gay L; Ali SM; Elvin JA; Singal G; Ross JS; Fabrizio D; Szabo PM; Chang H; Sasson A; Srinivasan S; Kirov S; Szustakowski J; Vitazka P; Edwards R; Bufill JA; Sharma N; Ou SI; Peled N; Spigel DR; Rizvi H; Aguilar EJ; Carter BW; Erasmus J; Halpenny DF; Plodkowski AJ; Long NM; Nishino M; Denning WL; Galan-Cobo A; Hamdi H; Hirz T; Tong P; Wang J; Rodriguez-Canales J; Villalobos PA; Parra ER; Kalhor N; Sholl LM; Sauter JL; Jungbluth AA; Mino-Kenudson M; Azimi R; Elamin YY; Zhang J; Leonardi GC; Jiang F; Wong KK; Lee JJ; Papadimitrakopoulou VA; Wistuba II; Miller VA; Frampton GM; Wolchok JD; Shaw AT; Jänne PA; Stephens PJ; Rudin CM; Geese WJ; Albacker LA; Heymach JV
    Cancer Discov; 2018 Jul; 8(7):822-835. PubMed ID: 29773717
    [No Abstract]   [Full Text] [Related]  

  • 5. Prognostic Value of KRAS Mutation Subtypes and PD-L1 Expression in Patients With Lung Adenocarcinoma.
    Tao L; Miao R; Mekhail T; Sun J; Meng L; Fang C; Guan J; Jain A; Du Y; Allen A; Rzeszutko BL; Socinski MA; Chang CC
    Clin Lung Cancer; 2021 Jul; 22(4):e506-e511. PubMed ID: 32807653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The KRAS
    Hallin J; Engstrom LD; Hargis L; Calinisan A; Aranda R; Briere DM; Sudhakar N; Bowcut V; Baer BR; Ballard JA; Burkard MR; Fell JB; Fischer JP; Vigers GP; Xue Y; Gatto S; Fernandez-Banet J; Pavlicek A; Velastagui K; Chao RC; Barton J; Pierobon M; Baldelli E; Patricoin EF; Cassidy DP; Marx MA; Rybkin II; Johnson ML; Ou SI; Lito P; Papadopoulos KP; Jänne PA; Olson P; Christensen JG
    Cancer Discov; 2020 Jan; 10(1):54-71. PubMed ID: 31658955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The outcomes of an impaired powerhouse in KRAS mutant lung adenocarcinoma cells by Elesclomol.
    Albayrak G; Korkmaz FD; Tozcu D; Dogan Turacli I
    J Cell Biochem; 2019 Jun; 120(6):10564-10571. PubMed ID: 30628735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concomitant genomic alterations in KRAS mutant advanced lung adenocarcinoma.
    Gibert J; Clavé S; Hardy-Werbin M; Taus Á; Rocha P; Longarón R; Piquer G; Chaib I; Carcereny E; Morán T; Salido M; Dalmases A; Bellosillo B; Arriola E
    Lung Cancer; 2020 Feb; 140():42-45. PubMed ID: 31862576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience.
    El Osta B; Behera M; Kim S; Berry LD; Sica G; Pillai RN; Owonikoko TK; Kris MG; Johnson BE; Kwiatkowski DJ; Sholl LM; Aisner DL; Bunn PA; Khuri FR; Ramalingam SS
    J Thorac Oncol; 2019 May; 14(5):876-889. PubMed ID: 30735816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KRAS Mutations in Lung Adenocarcinoma: Molecular and Epidemiological Characteristics, Methods for Detection, and Therapeutic Strategy Perspectives.
    Guibert N; Ilie M; Long E; Hofman V; Bouhlel L; Brest P; Mograbi B; Marquette CH; Didier A; Mazieres J; Hofman P
    Curr Mol Med; 2015; 15(5):418-32. PubMed ID: 25941815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KRAS
    Kyriakopoulos G; Katopodi V; Skeparnias I; Kaliatsi EG; Grafanaki K; Stathopoulos C
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of KRAS G12C mutation in lung adenocarcinoma stratified by stages and radiological features.
    Cao H; Ma Z; Li Y; Zhang Y; Chen H
    J Thorac Cardiovasc Surg; 2023 Dec; 166(6):e479-e499. PubMed ID: 37142051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative Systems Pharmacology Analysis of KRAS G12C Covalent Inhibitors.
    Stites EC; Shaw AS
    CPT Pharmacometrics Syst Pharmacol; 2018 May; 7(5):342-351. PubMed ID: 29484842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting KRAS mutant lung cancer: light at the end of the tunnel.
    Drosten M; Barbacid M
    Mol Oncol; 2022 Mar; 16(5):1057-1071. PubMed ID: 34951114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer.
    Wang H; Lv Q; Xu Y; Cai Z; Zheng J; Cheng X; Dai Y; Jänne PA; Ambrogio C; Köhler J
    EBioMedicine; 2019 Nov; 49():106-117. PubMed ID: 31668570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of wild type KRAS in KRAS
    Liu Y; Gao GF; Minna JD; Williams NS; Westover KD
    Lung Cancer; 2021 Mar; 153():73-80. PubMed ID: 33465697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KRASG12C mutant lung adenocarcinoma: unique biology, novel therapies and new challenges.
    Moldvay J; Tímár J
    Pathol Oncol Res; 2023; 29():1611580. PubMed ID: 38239281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.
    Liu C; Zheng S; Jin R; Wang X; Wang F; Zang R; Xu H; Lu Z; Huang J; Lei Y; Mao S; Wang Y; Feng X; Sun N; Wang Y; He J
    Cancer Lett; 2020 Feb; 470():95-105. PubMed ID: 31644929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of real-life data from patients with NGS panel negative and
    Gökyer A; Küçükarda A; Köstek O; Gökmen İ; Özcan E; Sayın S; Taştekin E; Hacıoğlu B; Erdoğan B; Uzunoğlu S; Çiçin İ
    Tumori; 2022 Apr; 108(2):141-146. PubMed ID: 33624577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MCL1 inhibition enhances the therapeutic effect of MEK inhibitors in KRAS-mutant lung adenocarcinoma cells.
    Tada M; Sumi T; Tanaka Y; Hirai S; Yamaguchi M; Miyajima M; Niki T; Takahashi H; Watanabe A; Sakuma Y
    Lung Cancer; 2019 Jul; 133():88-95. PubMed ID: 31200834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.